Baird analyst David Rescott lowered the firm’s price target on Nevro to $8 from $11 and keeps a Neutral rating on the shares. The firm noted they missed revenue estimates and delivered an EBITDA result ahead of expectations, though meaningfully lowered the FY24 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: